108499-32-7

Basic information

• Product Name: Methyl 5-(bromomethyl)-2-thiophenecarboxylate
• Synonyms: Methyl 5-(bromomethyl)-2-thiophenecarboxylate;5-(bromomethyl)-2-thiophenecarboxylate;2-Thiophenecarboxylic acid, 5-(bromomethyl)-, methyl ester
• CAS NO: 108499-32-7
• Molecular Formula: C₇H₇BrO₂S
• Molecular Weight: 235.09828
• Mol File: 108499-32-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Methyl 5-(bromomethyl)-2-thiophenecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-(bromomethyl)-2-thiophenecarboxylate(108499-32-7)
• EPA Substance Registry System: Methyl 5-(bromomethyl)-2-thiophenecarboxylate(108499-32-7)

Safety Data

• Hazardous Substances Data: 108499-32-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-(bromomethyl)-2-thiophenecarboxylate is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the development of new drugs and pharmaceutical products.
Used in Organic Synthesis:
Methyl 5-(bromomethyl)-2-thiophenecarboxylate is used as a key component in organic synthesis processes, enabling the creation of a wide range of chemical compounds.
Used in Agrochemical Industry:
Methyl 5-(bromomethyl)-2-thiophenecarboxylate is used as an intermediate in the production of agrochemicals, contributing to the development of effective and innovative agricultural products.
Used in Specialty Chemicals Industry:
Methyl 5-(bromomethyl)-2-thiophenecarboxylate is utilized in the manufacturing of specialty chemicals, playing a crucial role in the synthesis of unique and high-value chemical compounds.

Upstream product

• 19432-69-0 methyl 5-methylthiophene-2-carboxylate 
• 530145-16-5 5-hydroxymethyl-2-thiophenecarboxylic acid methyl ester 
• 1918-79-2 2-methylthiophene-5-carboxylic acid 
• 956117-83-2 5-(t-butyldimethyl-silanyloxymethyl)thiophene-2-carboxylic acid 
• 956117-84-3 5-(t-butyldimethyl-silanyloxymethyl)-thiophene-2-carboxylic acid methyl ester 

Downstream Products

• 1047668-31-4 C₁₉H₁₉Cl₂NO₄S 
• 1073242-23-5 C₂₁H₂₀N₂O₄S₂ 
• 1145677-19-5 C₂₀H₂₁Cl₂NO₄S 
• 960205-67-8 C₂₉H₄₃NO₆SSi 
• 1193781-77-9 C₄₀H₄₆N₂O₉S 
• 1209996-59-7 methyl 5-((4-(4-(3-(cyclopropylmethyl)ureido)benzoyl)piperazin-1-yl)methyl)thiophene-2-carboxylate 
• 1309436-19-8 ethyl (3S)-3-[4-[[5-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)-2-thienyl]methoxy]phenyl]hex-4-ynoate 
• 1309435-60-6 (3S)-3-[4-[[5-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)-2-thienyl]methoxy]phenyl]hex-4-ynoic acid 
• 1311291-25-4 5-(4-amidino-2-fluorophenoxycarbonyl)thiophen-2-ylacetic acid trifluoroacetic acid salt 
• 61855-04-7 5-methoxymethyl-thiophene-2-carboxylic acid 
• 142667-06-9 5-carboxymethylthiophene-2-carboxylic acid methyl ester 
• 1423018-12-5 (S)-3-(4-((5-((8-methoxy-3,4-dihydroquinolin-1(2H)-yl)methyl)thiophen-2-yl)methoxy)phenyl)hex-4-ynoic acid 
• 1423018-16-9 ethyl (S)-3-(4-((5-((8-methoxy-3,4-dihydroquinolin-1(2H)-yl)-methyl)thiophen-2-yl)methoxy)phenyl)hex-4-ynoate 
• 1423018-14-7 methyl 5-[(8-methoxy-3,4-dihydro-2H-quinolin-1-yl)methyl]thiophene-2-carboxylate 

Relevant articles and documents

Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by a progressive-fibrosing phenotype. IPF has been associated with aberrant HDAC activities confirmed by our immunohistochemistry studies on HDAC6 overexpression in IPF lung tissues. We herein developed a series of novelhHDAC6 inhibitors, having low inhibitory potency overhHDAC1 andhHDAC8, as potential pharmacological tools for IPF treatment. Their inhibitory potency was combined with lowin vitroandin vivotoxicity. Structural analysis of 6h and structure-activity relationship studies contributed to the optimization of the binding mode of the new molecules. The best-performing analogues were tested for their efficacy in inhibiting fibrotic sphere formation and cell viability, proving their capability in reverting the IPF phenotype. The efficacy of analogue 6h was also determined in a validated human lung model of TGF-β1-dependent fibrogenesis. The results highlighted in this manuscript may pave the way for the identification of first-in-class molecules for the treatment of IPF.

Discovery of thiophene-containing biaryl amide derivatives as novel glucagon receptor antagonists

A novel series of thiophene-containing biaryl amide glucagon receptor (GCGR) antagonists were designed and synthesized. Two compounds of this series, 14f and 14h, exhibited good GCGR binding (IC50?=?6.1 and 4.4?μm, respectively) and cAMP functional activities (IC50?=?4.4 and 14.4?μm, respectively). The possible binding modes of compounds 14f and 14h with GCGR were explored by molecular simulation.

Base promotedgem-difluoroolefination of alkyl triflones

A new synthesis ofgem-difluoroalkenes from readily available alkyl triflones and difluorocarbene precursors such as TMSCF2Br has been reported. The reaction, regardless of electronic effect, givesgem-difluoroalkenes in good to excellent yields. The mechanism may involve deprotonation of triflones, nucleophilic addition, and the elimination of SO2CF3

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of pretubulysin and analogs

We present herein a novel and convenient route for the scaling-up of the dTuv fragment of pretubulysin. The newly conceived chemical path involves a practical and efficient one-step procedure for the preparation of a key thiazole intermediate, followed by high-yielding Wittig olefination/reduction steps. The optimized route, starting from the inexpensive and non-toxic l-cysteine, encompasses five synthetic steps and only two chromatographic purifications, thus displaying a dramatically increased overall yield. The versatility of the proposed approach also provides new hints for the exploration of pretubulysin derivatives bearing diverse heterocyclic portions.

Effect of π-spacers and anchoring groups on the photovoltaic performances of ullazine-based dyes

Three ullazine-based organic sensitizers (QD1, QD2 and QD3) have been designed, synthesized, and characterized for dye-sensitized solar cells (DSSCs). Ullazine possesses some attractive properties, such as a planar π-system to promote intensely the intram

SELECTIVE HDAC6 INHIBITORS

The present invention provides hydroxamic acids of the formula described herein, that have activity toward inhibiting histone deacetylases, and in particular HDAC6. Also contemplated are pharmaceutical compositions and methods of use of an effective amount of the hydroxamic acid compounds provided, for treating a disease in a subject. In certain embodiments, the subject is afflicted with cancer, neurodegenerative disease, or HIV infection.

AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE

[Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conduct

A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

The present invention provides a compound of the formula below or a pharmaceutical salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.

SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS

A compound having the formula or a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. Y, A, U, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.